9 research outputs found

    ReflexiĂłn PolĂ­tica. Volumen 5 No. 10 de 2003

    Get PDF
    La democracia local es tema de la mayor importancia. Las instituciones colombianas desde 1991 la fortalecieron, a efecto de diputar a todo el pueblo para que, en cada lugar, atienda directamente sus propios problemas, y proteja mediante su acciĂłn de control administrativo los programas que, el mismo pueblo anhela, y plantea antes de la escogencia de sus mandatarios. En Colombia se estĂĄ implantando una reforma polĂ­tica que ha modificado el sistema electoral, orientada a fortalecer los partidos polĂ­ticos, fuentes del poder y sustento de la democracia como sistemaLocal democracy is a matter of the greatest importance. Since 1991, Colombian institutions have strengthened it, in order to deputize all the people so that, in each place, they directly address their own problems, and protect through their action of administrative control the programs that the people themselves long for, and propose before the choice of their leaders. In Colombia, a political reform is being implemented that has modified the electoral system, aimed at strengthening political parties, sources of power and support of democracy as a system

    Seminario Integrador 2 - ME169 - 202101

    No full text
    Curso de la especialidad de la carrera de medicina, de carĂĄcter teĂłrico del ciclo 9, en el que los estudiantes al realizar la revisiĂłn y anĂĄlisis de casos, elaboran los diagnĂłsticos, los planes de trabajo y terapĂ©uticos pertinentes para el caso clĂ­nico respectivo. El curso de seminario integrador 2 busca desarrollar las competencias generales de: comunicaciĂłn oral (nivel 3) 1y las competencias especĂ­ficas de prĂĄctica clĂ­nica-promociĂłn, prevenciĂłn y tratamiento (nivel 2) y profesionalismo- aprendizaje autonĂłmo y desarrollo profesional (nivel 3). El curso de seminario integrador 2 les permitirĂĄ a los estudiantes tomar decisiones ante los diferentes retos diagnĂłsticos del paciente adulto con un problema mĂ©dico o quirĂșrgico como miembro de un equipo interprofesional en su futura vida profesional

    Seminario Integrador 2 - ME169 - 202102

    No full text
    Curso de la especialidad de la carrera de medicina, de carĂĄcter teĂłrico del ciclo 9, en el que los estudiantes al realizar la revisiĂłn y anĂĄlisis de casos, elaboran los diagnĂłsticos, los planes de trabajo y terapĂ©uticos pertinentes para el caso clĂ­nico respectivo. El curso de seminario integrador 2 busca desarrollar las competencias generales de: comunicaciĂłn oral (nivel 3) 1y las competencias especĂ­ficas de prĂĄctica clĂ­nica-promociĂłn, prevenciĂłn y tratamiento (nivel 3) y profesionalismo- aprendizaje autonĂłmo y desarrollo profesional (nivel 3). El curso de seminario integrador 2 les permitirĂĄ a los estudiantes tomar decisiones ante los diferentes retos diagnĂłsticos del paciente adulto con un problema mĂ©dico o quirĂșrgico como miembro de un equipo interprofesional en su futura vida profesional

    Mural Endocarditis: The GAMES Registry Series and Review of the Literature

    No full text

    Myocardial T1 and T2 mapping by magnetic resonance in patients with immune checkpoint inhibitor–associated myocarditis

    No full text
    BACKGROUND Myocarditis is a potentially fatal complication of immune checkpoint inhibitor (ICI) therapy. Data on the utility of cardiovascular magnetic resonance (CMR) T1 and T2 mapping in ICI myocarditis are limited. OBJECTIVES This study sought to assess the value of CMR T1 and T2 mapping in patients with ICI myocarditis. METHODS In this retrospective study from an international registry of patients with ICI myocarditis, clinical and CMR findings (including T1 and T2 maps) were collected. Abnormal T1 and T2 were defined as 2 SD above site (vendor/field strength specific) reference values and a z-score was calculated for each patient. Major adverse cardiovascular events (MACE) were a composite of cardiovascular death, cardiogenic shock, cardiac arrest, and complete heart block. RESULTS Of 136 patients with ICI myocarditis with a CMR, 86 (63%) had T1 maps and 79 (58%) also had T2 maps. Among the 86 patients (66.3 13.1 years of age), 36 (41.9%) had a left ventricular ejection fraction <55%. Across all patients, mean z-scores for T1 and T2 values were 2.9 1.9 (p < 0.001) and 2.2 2.1 (p < 0.001), respectively. On Siemens 1.5-T scanner (n ÂŒ 67), native T1 (1,079.0 55.5 ms vs. 1,000.3 22.1 ms; p < 0.001) and T2 (56.2 4.9 ms vs. 49.8 2.2 ms; p < 0.001) values were elevated compared with reference values. Abnormal T1 and T2 values were seen in 78% and 43% of the patients, respectively. Applying the modified Lake Louise Criteria, 95% met the nonischemic myocardial injury criteria and 53% met the myocardial edema criteria. Native T1 values had excellent discriminatory value for subsequent MACE, with an area under the curve of 0.91 (95% confidence interval: 0.84 to 0.98). Native T1 values (for every 1-unit increase in z-score, hazard ratio: 1.44; 95% confidence interval: 1.12 to 1.84; p ÂŒ 0.004) but not T2 values were independently associated with subsequent MACE. CONCLUSIONS The use of T1 mapping and application of the modified Lake Louise Criteria provides important diagnostic value, and T1 mapping provides prognostic value in patients with ICI myocarditis. (J Am Coll Cardiol 2021;77:1503–16) © 2021 by the American College of Cardiology Foundation

    Global circumferential and radial strain among patients with immune checkpoint inhibitor myocarditis

    No full text
    BACKGROUND Global circumferential strain (GCS) and global radial strain (GRS) are reduced with cytotoxic chemotherapy. There are limited data on the effect of immune checkpoint inhibitor (ICI) myocarditis on GCS and GRS. OBJECTIVES This study aimed to detail the role of GCS and GRS in ICI myocarditis. METHODS In this retrospective study, GCS and GRS from 75 cases of patients with ICI myocarditis and 50 ICI-treated patients without myocarditis (controls) were compared. Pre-ICI GCS and GRS were available for 12 cases and 50 controls. Measurements were performed in a core laboratory blinded to group and time. Major adverse cardiovascular events (MACEs) were defined as a composite of cardiogenic shock, cardiac arrest, complete heart block, and cardiac death. RESULTS Cases and controls were similar in age (66 15 years vs 63 12 years; P ÂŒ 0.20), sex (male: 73% vs 61%; P ÂŒ 0.20) and cancer type (P ÂŒ 0.08). Pre-ICI GCS and GRS were also similar (GCS: 22.6% 3.4% vs 23.5% 3.8%; P ÂŒ 0.14; GRS: 45.5% 6.2% vs 43.6% 8.8%; P ÂŒ 0.24). Overall, 56% (n ÂŒ 42) of patients with myocarditis presented with preserved left ventricular ejection fraction (LVEF). GCS and GRS were lower in myocarditis compared with on-ICI controls (GCS: 17.5% 4.2% vs 23.6% 3.0%; P < 0.001; GRS: 28.6% 6.7% vs 47.0% 7.4%; P < 0.001). Over a median follow-up of 30 days, 28 cardiovascular events occurred. A GCS (HR: 4.9 [95% CI: 1.6-15.0]; P ÂŒ 0.005) and GRS (HR: 3.9 [95% CI: 1.4-10.8]; P ÂŒ 0.008) below the median was associated with an increased event rate. In receiveroperating characteristic (ROC) curves, GCS (AUC: 0.80 [95% CI: 0.70-0.91]) and GRS (AUC: 0.76 [95% CI: 0.64-0.88]) showed better performance than cardiac troponin T (cTnT) (AUC: 0.70 [95% CI: 0.58-0.82]), LVEF (AUC: 0.69 [95% CI: 0.56-0.81]), and age (AUC: 0.54 [95% CI: 0.40-0.68]). Net reclassification index and integrated discrimination improvement demonstrated incremental prognostic utility of GRS over LVEF (P ÂŒ 0.04) and GCS over cTnT (P ÂŒ 0.002). CONCLUSIONS GCS and GRS are lower in ICI myocarditis, and the magnitude of reduction has prognostic significance. (J Am Coll Cardiol Img 2022;15:1883–1896) © 2022 the American College of Cardiology Foundation. Published by Elsevier. All rights reserved

    Monetary Policy, Implicit Interest Rate, and Relative Net Trade Credit

    No full text

    Evaluation of a quality improvement intervention to reduce anastomotic leak following right colectomy (EAGLE): pragmatic, batched stepped-wedge, cluster-randomized trial in 64 countries

    Get PDF
    Background Anastomotic leak affects 8 per cent of patients after right colectomy with a 10-fold increased risk of postoperative death. The EAGLE study aimed to develop and test whether an international, standardized quality improvement intervention could reduce anastomotic leaks. Methods The internationally intended protocol, iteratively co-developed by a multistage Delphi process, comprised an online educational module introducing risk stratification, an intraoperative checklist, and harmonized surgical techniques. Clusters (hospital teams) were randomized to one of three arms with varied sequences of intervention/data collection by a derived stepped-wedge batch design (at least 18 hospital teams per batch). Patients were blinded to the study allocation. Low- and middle-income country enrolment was encouraged. The primary outcome (assessed by intention to treat) was anastomotic leak rate, and subgroup analyses by module completion (at least 80 per cent of surgeons, high engagement; less than 50 per cent, low engagement) were preplanned. Results A total 355 hospital teams registered, with 332 from 64 countries (39.2 per cent low and middle income) included in the final analysis. The online modules were completed by half of the surgeons (2143 of 4411). The primary analysis included 3039 of the 3268 patients recruited (206 patients had no anastomosis and 23 were lost to follow-up), with anastomotic leaks arising before and after the intervention in 10.1 and 9.6 per cent respectively (adjusted OR 0.87, 95 per cent c.i. 0.59 to 1.30; P = 0.498). The proportion of surgeons completing the educational modules was an influence: the leak rate decreased from 12.2 per cent (61 of 500) before intervention to 5.1 per cent (24 of 473) after intervention in high-engagement centres (adjusted OR 0.36, 0.20 to 0.64; P &lt; 0.001), but this was not observed in low-engagement hospitals (8.3 per cent (59 of 714) and 13.8 per cent (61 of 443) respectively; adjusted OR 2.09, 1.31 to 3.31). Conclusion Completion of globally available digital training by engaged teams can alter anastomotic leak rates. Registration number: NCT04270721 (http://www.clinicaltrials.gov)
    corecore